Company Announcements
HalcyGen Pharmaceuticals Ltd ACN 115 832 963
‘A strategic license based partnership with Mayne Pharma International'
Appointment of Head of Marketing - 18 March 2010
HGN_SUBA_UK PK Study Results - 2 March 2010
Warner Chilcott Quarter Results Doryx - 2 March 2010
Appendix 4C Quarterly Cash Flow - 29 January 2010
Ammended Paragraph IV Notice - 11 January 2010
Halcygen Distribution Notice - 15 December 2009
Mayne Pharma Acquisition Complete - 18 November 2009
Mayne Pharma Acquisition Announcement - 28 September 2009
HGN Mayne Pharma Acquisition Presentation - 25 September 2009
European Registration Strategy - 22 July 2009
ASX PK Dose Completion - 21 November 2008
ASX First Successful Pivotal PK Trial_16 October 2008
ASX PK Dose Completion_17 July 2008
CEO Forum Series Lunch
ASX Ind Approval June 2008
ASX Oncology June_11_2008
Clinical Development and Registration of SubaItraconazole
ASX Itraconazole Commercial Scale Manufacture
Potential Application for Subazole in Oncology
FDA Provides Guidance on Registration Study
Results of the Annual General Meeting Held 20 November 2007
Appointment of Non- Executive Director
Successful second Clinical Study for SUBA-Itraconazole
HalcyGen anti-fungal drug passes clinical test - to enter Phase III trial in 2007/08 [PDF]
Subscribe For Company Announcements
|
|
| 
